Fig. 9

Effect of KYP-2047 on TGF-β and α-SMA markers. Immunohistochemical analyses of TGF-β: Sham group (A), and BLM group (B); KYP-2047 treatments after BLM: KYP-2047 2.5 mg/kg (C) and KYP-2047 5 mg/kg (D). See percentage of total tissue area (E). Images were shown at ×20 magnification. Pulmonary TGF-β mRNA was measured by qRT-PCR (F). Western blot analyses showed an important decrease of α-SMA after KYP-2047 treatments compared to BLM group (G). Data are representative of at least three independent experiments. One way ANOVA test ***p < 0.001 vs Sham; ^##p < 0.01 vs BLM; ^###p < 0.001 vs BLM